Holen Sie sich die Stockscreener-App
9.07
4.12%
-0.39
Handel nachbörslich:
9.12
0.05
+0.55%
Schlusskurs vom Vortag:
$9.46
Offen:
$9.7
24-Stunden-Volumen:
231.03K
Relative Volume:
1.03
Marktkapitalisierung:
$819.20M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
97.01
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
+4.49%
1M Leistung:
-5.22%
6M Leistung:
-27.50%
1J Leistung:
-12.87%
1-Tages-Spanne:
$9.02
$9.775
1-Wochen-Bereich:
$9.02
$11.61
52-Wochen-Spanne:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(619) 949-3681
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
9.07 | 784.01M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN
Gyre Therapeutics Closes $23 Million Public Offering - marketscreener.com
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - TradingView
Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga
GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World
Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus
Gyre Therapeutics Announces Stock Offering Agreement - TipRanks
Gyre Therapeutics announces new stock offering - Investing.com
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Gyre Therapeutics commences underwritten public offering - MSN
Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com
GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus
Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan
Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance
Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus
Gyre Therapeutics tumbles after stock offering launch - TradingView
Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com
Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus
Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025 - Nasdaq
Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan
Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World
Gyre Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq
1 Stock to Buy Hand Over Fist as ‘Risk On’ Sentiment Gains Momentum - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq
Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com
Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance
Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
GNI Group Confirms NDA Timeline for Hydronidone - TipRanks
VOO ETF News, 4/17/2025 - The Globe and Mail
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada
Is Google Stock a Buy, Sell, or Hold on Potential CoreWeave GPU Deal? - The Globe and Mail
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):